Product Information
REPAGLINIDE 2 MG TABLET is a generic product labeled by Chartwell RX LLC, priced at $0.0925 per EA under NDC 62135094890. Its NADAC has been published 43 times since Dec 10, 2025.
FDA first approved this application on Nov 22, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Chartwell RX LLCNDC
62135094890
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
REPAGLINIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078555FDA Approved
11/22/2013
TE Code
AB
On Market Since
1/22/2014
Pharmacological Classes
Price Statistics
The NADAC for REPAGLINIDE 2 MG TABLET has been published 43 times since Dec 10, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0925 per EA |
|---|---|
| All-time high | $0.0966 (Jan 14, 2026) |
| All-time low | $0.0859 (Mar 18, 2026) |
| 52-week high | $0.0966 |
| 52-week low | $0.0859 |
| Median price | $0.0910 |
| Average price | $0.0909 |
| Largest weekly change | +10.7% (Aug 19, 2026) |
| Weeks tracked | 43 |
| Tracking since | Dec 10, 2025 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Repaglinide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Glinide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of REPAGLINIDE 2 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for REPAGLINIDE 2 MG TABLET, manufactured by Chartwell RX LLC, is $0.0925 per EA (NDC 62135094890), effective Sep 30, 2026.
How has the price of REPAGLINIDE 2 MG TABLET changed over time?
Over the history we have for it, the NADAC for REPAGLINIDE 2 MG TABLET has held within roughly two percent of its current level. It has been tracked across 43 weekly CMS publications since Dec 10, 2025.
What are the highest and lowest recorded NADAC prices for REPAGLINIDE 2 MG TABLET?
Since Dec 10, 2025, the NADAC for REPAGLINIDE 2 MG TABLET has ranged from a low of $0.0859 (Mar 18, 2026) to a high of $0.0966 (Jan 14, 2026), with a median of $0.0910 per EA.
Are there cheaper alternatives to REPAGLINIDE 2 MG TABLET?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as REPAGLINIDE 2 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures REPAGLINIDE 2 MG TABLET?
REPAGLINIDE 2 MG TABLET (NDC 62135094890) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.